Continuation of Protease-Inhibitor Based Second-Line Therapy vs. Switch to B/F/TAF in Virologically Suppressed Adults
Conditions: HIV-1-infection; Antiretroviral Therapy Interventions: Drug: Continuation of boosted PI; Drug: B/F/TAF Sponsors: Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic; Brigham and Women's Hospital; Harvard Medical School; Analysis Group, Inc.; Weill Medical College of Cornell University Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials